Fluor Corporation (NYSE: FLR) today announced that its UK subsidiary,
Fluor Limited, has been awarded a contract by Pfizer Limited for the
construction management and commissioning of a pharmaceutical
development facility in Sandwich, Kent, England. The value of the
project to Fluor is approximately $113 million and was booked in the
fourth quarter of 2001.
The Sandwich complex serves as Pfizer's headquarters for drug research
and development in Europe. When completed, the building, known as B530,
will include five-stories of nearly 390,000 square feet of office space,
laboratories and ancillary facilities. Construction began in December
2001, with completion scheduled for summer of 2004.
"We are delighted to be selected by Pfizer for this important project.
It continues the developing relationship between our two companies and
supports Fluor's strategies of repeat business and growth in the
European Life Sciences marketplace," said Ken L. Smith, a president
within Fluor's Industrial & Infrastructure group. "Pfizer's B530 project
will benefit from experience gained by Fluor on past Pfizer projects,
including refined work practices, methodologies and team communication."
Fluor Corporation provides services on a global basis in the fields of
engineering, procurement, construction, operations, maintenance and
project management. Headquartered in Aliso Viejo, California, Fluor is a
Fortune 500 company with revenues of $9 billion in fiscal year 2001. For
more information, visit www.fluor.com.
For further information, please contact: Janet Kearns, Media Relations
(UK), +44 (0) 20 8222 7057, or fax, +44 (0) 20 8222 7059; or Lori
Serrato, Media Relations (USA), +1-949-349-7420, both of Fluor
Corporation.
Janet Kearns, Media Relations (UK), +44 (0) 20 8222 7057, orfax, +44 (0) 20 8222 7059; or Lori Serrato, Media Relations (USA),+1-949-349-7420, both of Fluor Corporationhttp://www.fluor.com